Skip to main content

Artelo Biosciences, Inc.

ARTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001621221

No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Artelo Biosciences, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of ARTL: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders159−6
Shares1.40M134.6K−1.27M (−90.4%)
Value$442.8K$464.0K+$21.2K (+4.8%)

New holders (2)

Institutions that held Artelo Biosciences, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to ARTL in Q3 2022
InstitutionSharesValue% of portfolio
Two Sigma Advisers, LP35,062$121.0K0.00%
Two Sigma Investments, LP10,608$37.0K0.00%

Sold out (8)

Institutions that held Artelo Biosciences, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of ARTL in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Snowden Capital Advisors LLC110,000$34.0K
Bank of New York Mellon Corp86,016$27.0K
Susquehanna International Group, LLP80,080$25.0K
Northern Trust Corp62,521$20.0K
Virtu Financial LLC63,193$20.0K
HighTower Advisors, LLC44,000$14.0K
StoneX Group Inc.15,000$4.75K
State Street Corp13,039$4.00K